• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Australian Startup DoseMe Raises $2.6M for Precision Dosing

by Fred Pennic 08/26/2016 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

DoseMe

DoseMe, an Australian digital health startup has raised $2.6 million in Series A funding to expand its precision dosing platform. The company plans to utilize the latest round of funding to commercialize DoseMe in Australia, expand into the US and European markets and integrate with existing EMRs in key markets.  

Founded in 2012 by Dr Robert McLeay, the recent funding round was filled by Greg Spurgin and Gary Cunningham who co-founded an US outpatient orthopedic physical therapy company Results Physiotherapy, the DoseMe software platform is a simple-to-use precision dosing tool.

How DoseMe Works

Built on the principles of Bayesian dose forecasting, a complex mathematical algorithm that uses patient data and laboratory results to estimate a person’s metabolism – their ability to absorb, process and clear a drug from their system. 

DoseMe achieves this by building a virtual model of each person, from as little as one laboratory result, by using thousands of data points from published population models. Once this virtual model of each individual is built – in less than a second – DoseMe helps clinicians dose more accurately, and precisely, calculating the most effective dose to reach the desired outcome. DoseMe continues to learn over time; continuously becoming more refined in its dose recommendations.

In addition, DoseMe can simulate the potential outcome of different dosing regimens to support clinicians in making the best decision for challenging cases.

Key patient benefits and cost savings of the platform include:  

– Increase childhood leukaemia survival by > 10% 

– Halve side-effects for chemotherapy. 

– Increase patients in therapeutic range from 35% to > 90%. 

– Reduce mortality by 50%. 

– Save more than $2,500 USD per patient. 

– Reduce hospital stay length by up to 16 days per patient. 

– Cost-benefit ratio between 4:1 and 52:1 

Additionally, DoseMe plans to expand the number of drug molecules on the platform (including regulatory costs for each molecule in Australia (Therapeutic Goods Administration), Europe (CE) where DoseMe has medical regulatory clearance, and the US (FDA) where DoseMe’s submission is currently being reviewed.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: DoseMe

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Moving Beyond EHRs: What Lies Ahead for Healthcare Digitization?

AI Agents vs. Chatbots: Understanding Agentic AI’s Role in Healthcare

AI Breakthrough Reveals 2025 AI Breakthrough Award Winners

AI Breakthrough Reveals 2025 AI Breakthrough Award Winners

Healthcare's Big Blind Spot: The Measurement Crisis in Inpatient Psychiatry

Healthcare’s Big Blind Spot: The Measurement Crisis in Inpatient Psychiatry

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |